Henderson, United States
Volition, established in 2010, is on a mission to transform the landscape of disease diagnosis through its cutting-edge epigenetic technologies. Headquartered in the United States and listed on NYSE AMERICAN under VolitionRX Limited (VNRX), this innovative company seeks to change how diseases such as cancer and sepsis are diagnosed and monitored.
With a focus on early detection via routine blood tests, Volition uses patented technologies to identify biomarkers like nucleosomes and transcription factors. Their flagship Nu.Q® technology is structured around four main pillars: Nu.Q® Vet, Nu.Q® NETs, Nu.Q® Discover, and Nu.Q® Cancer. Additionally, their Capture-PCR™ offers a pioneering liquid biopsy method for swift cancer detection.
The company’s recent $100.00K Post-IPO equity investment on March 26, 2024, underscores growing investor confidence. With ongoing clinical trials for human medicine and successful applications in veterinary care, Volition is positioned for substantial growth, aimed at saving lives worldwide.
